Uy Ear
Stock Analyst at Mizuho
(3.11)
# 1,201
Out of 4,960 analysts
66
Total ratings
46.15%
Success rate
13.51%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $24 | $25.74 | -6.76% | 13 | Aug 7, 2025 | |
| MBX MBX Biosciences | Initiates: Outperform | $38 | $14.33 | +165.18% | 1 | Aug 5, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $40 → $14 | $20.22 | -30.76% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $26.18 | +224.68% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $15.99 | +31.37% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $15.70 | +27.39% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.63 | +59.49% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $29.75 | +34.45% | 5 | Nov 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $11.23 | +256.19% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $7.68 | +199.48% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $135.43 | +3.37% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $179.29 | -77.69% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.62 | +517.28% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.01 | +197.03% | 2 | Mar 1, 2023 |
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $25.74
Upside: -6.76%
MBX Biosciences
Aug 5, 2025
Initiates: Outperform
Price Target: $38
Current: $14.33
Upside: +165.18%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $40 → $14
Current: $20.22
Upside: -30.76%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $26.18
Upside: +224.68%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $15.99
Upside: +31.37%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $15.70
Upside: +27.39%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.63
Upside: +59.49%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $29.75
Upside: +34.45%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $11.23
Upside: +256.19%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $7.68
Upside: +199.48%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $135.43
Upside: +3.37%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $179.29
Upside: -77.69%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.62
Upside: +517.28%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.01
Upside: +197.03%